An Amgen (AMGN) employee violated Danish law by sharing and liking a U.S. press release about a medicine on LinkedIn, but will not be sanctioned, nor is the company being held responsible for the incident, the Danish Medicines Agency has decided. The employee could have faced up to four months in jail and the drug maker might have been liable for a penalty.

The press release in question was issued last August and contained positive study results about the Kyprolis cancer treatment when compared with another medicine called Velcade. And the results indicated that Kyprolis should replace Velcade as the standard of care when a patient relapses with multiple myeloma.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy